New portable nasal nitric oxide (nNO) analyser differentiates primary ciliary dyskinesia (PCD) from healthy individuals

NO way! Nasal nitric oxide measurement in infants

“…Additionally, non-specialist centres need training to conduct the measurements and interpret the results. Local testing might utilise portable electrochemical analysers rather than "gold standard" chemoluminescence analysers; a newly "Conformité Européene" (CE)-marked portable nNO analyser is an improvement on previous portable models, with an nNO trace allowing the technician to visualise peak nNO readings [31]. As portable NO analysers become more widespread for use in asthma, the opportunity for nNO measurements of infants at centres without PCD diagnostics is potentially useful, but only if measured by technicians who have received training, in correctly selected patients.…”

Key paediatric messages from the 2017 European Respiratory Society International Congress

“…Data from 12 international cohorts on PCD, presented by H albeisen et al [ 40 ], reported poor adherence to the 2009 consensus recommendations, due to the decrease in use of EM and the low use of test combinations, and suggest the need to implement the more recent evidence-based guidelines published by the ERS PCD Task Force [ 41 ]. Potential technologies to support diagnosis include a new portable nNO analyser (NIOX VERO nasal application; Circassia Pharmaceuticals Inc., Oxford, UK), which L ucas et al [ 42 ] reported can be used to differentiate patients with PCD from healthy individuals, and electron tomography (an extension of EM that produces high-resolution three-dimensional ultrastructural reconstructions), which S hoemark et al [ 43 ] reported is effective in identifying defects that are difficult to identify using conventional EM. Indeed, the accuracy of currently available tests in PCD diagnosis remains sometimes questionable [ 41 ].…”